Status:

COMPLETED

Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects

Lead Sponsor:

Beth Israel Deaconess Medical Center

Collaborating Sponsors:

Schering-Plough

Conditions:

Hepatitis C

Eligibility:

All Genders

18-65 years

Brief Summary

The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.

Detailed Description

Subjects with non-cirrhotic hepatitis C will have a magnetic resonance imaging (MRI)/magnetic resonance (MR) spectroscopy and neuropsychological testing prior to starting interferon. Subjects will hav...

Eligibility Criteria

Inclusion

  • Adults (\>18 years old) of both sexes with chronic HCV infection (all genotypes).
  • Subjects due to start treatment with pegylated interferon-alpha (IFN-a) for HCV eradication.
  • Subjects with chronic hepatitis C who have elected not to be treated with pegylated-IFN-a
  • Subjects with mild fibrosis on liver biopsy (stage 0-III/IV fibrosis)
  • Subjects able to give informed consent.
  • Subjects with controlled depression currently taking anti-depressant medication.

Exclusion

  • Subjects with cirrhosis on liver biopsy.
  • Subjects with active alcohol or drug abuse.
  • Subjects co-infected with human immunodeficiency virus (HIV).
  • Subjects with structural brain abnormality, past history of cerebrovascular accident (CVA) or serious head trauma.
  • Subjects with seizure disorder.
  • Subjects with any contraindication to IFN therapy.
  • Subjects with a poor command of the English language.
  • Subjects with a contraindication to MRI, e.g. pacemaker, claustrophobia.

Key Trial Info

Start Date :

March 1 2004

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT00136214

Start Date

March 1 2004

End Date

March 1 2008

Last Update

July 12 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215